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INTRODUCTION 
 
I. Characterization of S-nitrosoglutathione Reductase 
S-nitrosoglutathione reductase (GSNOR) also known as glutathione- 
dependent formaldehyde dehydrogenase (FDH), is a zinc-dependent 
dehydrogenase.  It is a member of the alcohol dehydrogenase (ADH) family and is 
also called Class III alcohol dehydrogenase.  The substrate specificity of GSNOR 
has been well studied (Holmquist and Vallee, 1991; Wagner et al., 1984).  It 
oxidizes long chain alcohols to an aldehyde with the help of a molecule of NAD+ 
(Figure 1).  Alcohols with a carbon chain longer than four carbons and containing 
a carboxyl group at the opposite end are metabolized by GSNOR much more 
efficiently than ethanol (Sanghani et al., 2000; Wagner et al., 1984) an example is 
12-hydroxydodecanoic acid (Figure 2A).  As the carbon chain length of alcohol 
increases, the Km of the alcohol decreases (Wagner et al., 1984). 
 
 
Figure 1.  GSNOR Catalytic Reaction.  GSNOR oxidizes an alcohol 
to aldehyde using NAD+ as a coenzyme. 
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 GSNOR was initially identified as FDH because of its role in the 
formaldehyde detoxification pathway.  Hydroxymethylglutathione (HMGSH) is 
formed by the spontaneous reaction of formaldehyde and glutathione (GSH).  
FDH oxidizes HMGSH to S-formylglutathione (Figure 2B) with the help of 
NAD+.  S-formylglutathione is further converted to formic acid and glutathione 
enzymatically by S-formylglutathione hydrolase.  Removal of formaldehyde from 
the cells protects the cells from its detrimental effects.  Formaldehyde is 
detrimental to cells because it can modify proteins, damage membranes, and cause 
mutagenesis through DNA-protein cross-links (Barber and Donohue, 1998).  
Formaldehyde was commonly used as a fixative for cell and tissue cultures until it 
was declared a carcinogen. 
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A) 
 
 
B) 
 
Figure 2.  Substrates for GSNOR.  A) In vitro reaction of GSNOR:  
12-HDDA is an example of a long chain primary alcohol with a 
carboxyl group which GSNOR oxidizes to an aldehyde.  B) GSNOR 
plays a key role in the removal of formaldehyde from the body.  
Formaldehyde spontaneously reacts with GSH to form HMGSH, 
GSNOR catalyzes the reaction of HMGSH to S-formylglutathione 
which is hydrolyzed to glutathione and formic acid by S-
formylglutathione hydrolase. 
 
 
The crystal structure of GSNOR has been determined (Yang et al., 1997) 
and the enzyme exists as a homodimer in its native state.  GSNOR contains a 
coenzyme binding site for NAD+/NADH and a substrate binding site for GSNO or 
long chain alcohols (Figure 3).   
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Figure 3.  Structure of GSNOR Homodimer.  Each GSNOR 
monomer contains a zinc ion, coenzyme binding site for NADH, and 
catalysis binding site for substrate.  
 
 
GSNOR is ubiquitously expressed in tissues as compared to other ADHs 
(Kaiser et al., 1989; Sanghani et al., 2000; Estonius et al., 1996).  One 
characteristic of ubiquitously expressed genes is the absence of a TATA box or a 
CAAT box in its promoter region (Hur and Edenberg, 1992), as is the case in 
GSNOR.  GSNOR is a highly conserved enzyme and can be found in both 
prokaryotic and eukaryotic organisms.  GSNOR has been maintained throughout 
evolution and is vital for NO homeostasis as a regulator for protein S-nitrosation 
through the reduction of GSNO (Liu et al., 2001).  Although GSNOR is expressed 
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in all tissue, its activity levels are highest in the liver followed by kidney, heart, 
lung, spleen and thymus (Liu et al., 2004).       
GSNOR was very well characterized as FDH until a report by Liu et al. 
identified NADH dependent GSNO-metabolizing enzyme as FDH by mass 
spectrophotometry (Liu et al., 2001).  Subsequent studies revealed the GSNOR’s 
oxidation rate for HMGSH is two to eight fold higher when GSNO is available 
than for HMGSH alone (Staab et al., 2008).  The only S-nitrosothiol (SNO) 
substrate recognized by GSNOR is GSNO (Liu et al., 2004).  A transnitrosation 
reaction transfers NO from nitrosylated proteins or S-nitrosothiols (RSNO) to 
glutathione to form S-nitrosoglutathione.  This GSNO is finally converted to 
glutathione disulfide (GSSG) by a two step mechanism.  First, GSNOR reduces 
GSNO to N-hydroxysulfenamide-glutathione (Fukuto et al., 2005) in the presence 
of NADH followed by non-enzymatic reaction of N-hydroxysulfenamide-
glutathione and glutathione to glutathione disulfide and hydroxylamine (Figure 4).  
Cellular GSNO is a nitric oxide reservoir that can either transfer to or remove from 
the proteins a NO group.  Reduction of GSNO by GSNOR depletes this reservoir 
and therefore indirectly regulates protein nitrosylation.   
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Figure 4.  GSNOR Reduction of GSNO.  The figure above shows 
the reduction of GSNO by GSNOR to a final product of GSSG and 
hydroxylamine. 
 
 
 
II. Effects of the Inhibition of GSNOR 
The role of GSNOR in NO metabolism is very well established by studies 
in GSNOR knockout mice (Liu et al., 2004).  The effect of inhibition in GSNOR 
should result in an increase in RSNOs which is what was observed in GSNOR 
knockout mice (Liu et al., 2004).  After treatment with lipopolysaccharide, 
RSNOs in  GSNOR-/- mice increased 3.3-fold and 29-fold over wild-type (WT) 
mice at 24 and 48 hours, respectively.  Of the RSNOs in the GSNOR-/- mice 90% 
are RSNOs with molecular weights >5000 (Liu et al., 2004).  This increase in 
RSNOs effects vascular homeostasis, asthma, and cystic fibrosis.  Hypotension 
was amplified in anesthetized GSNOR-/- mice over WT mice.  The basal levels of 
SNOs in RBC’s from GSNOR-/- mice were 2-fold higher, this amount would cause 
vasodilation in bioassays (Liu et al., 2004).  In the study by Que et al., WT mice 
exposed to the allergen ovalbumin exhibited airway hyperresponsivity and were 
depleted of lung SNOs likely due to increased GSNOR activity seen in these mice.  
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In the same study, GSNOR-/- mice do not show airway hyperresponsivity upon 
exposure to ovalbumin (Que et al., 2005).  Using a Human Airway Bioassay 
technique, Gaston et al. documented GSNO concentrations in asthma patients to 
be much lower than in control patients and correlated inversely to NO 
concentrations (Gaston et al., 1993).  Elevated NO in patient’s exhaled air, is one 
of the top symptoms in the diagnosis of asthma (Que et al., 2005).  A depletion of 
GSNO in the airway lining fluid (ALF) of asthmatic patients also correlates with 
this symptom.  In a clinical study, asthma patients have shown to have two times 
higher GSNOR activity than controls and depleted GSNO and SNOs in 
bronchoalveolar samples (Que et al., 2009).  Asthma and cystic fibrosis patients 
have a decrease in GSNO concentration in the airway lining fluid.  One treatment 
being investigated for cystic fibrosis patients is inhaling aerosolized GSNO (Foster 
et al., 2003; Zaman et al., 2006).  GSNOR inhibitors which can increase the basal 
GSNO levels will be another potential therapy. 
 
III. Effects on NF-κB Pathway  
The NF-κB Pathway is regulated by series of positive and negative 
regulatory elements.  Positive regulation causes phosphorylation of IKKβ, which 
in turn phosphorylates IκB.  IκBα is an inhibitory molecule that sequesters NF-κB 
in the cytosol.  Phosphorylation of IκBα targets it for ubiquination and 
proteasomal degradation releasing NF-κB (Figure 5).  NF-κB then travels to the 
nucleus and initiates transcription of cytokines, chemokines, which includes genes 
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such as NOS, tumor necrosis factor alpha, (TNFα), intercellular adhesion molecule 
(ICAM), and self regulation.  ICAM is a transmembrane protein (mICAM) or a 
soluble protein (sICAM) which is produced in epithelial cells and leukocytes 
(Hayden et al., 2006; Whiteman and Spiteri, 2008).  ICAM adheres the leukocytes 
to the affected endothelial cells.  Leukocytes are the defense mechanism of the 
body and will migrate into the infected tissue (Hayden et al., 2006).  Mice that 
have inadequate amounts of p65 NF-κB lack the ability to adhere leukocytes to the 
epithelial cells which slows the immune response (Hayden et al., 2006).  
The role of nitric oxide in regulation of NF-κB pathway is reviewed by 
Bove and van der Vliet (Bove and van der Vliet, 2006).  IKKβ has been shown to 
be a direct target for SNO modification resulting in decreased IKKβ activity 
causing inhibition of NF-κB dependent transcription (Reynaert et al., 2004).  
Asthma is the overstimulated inflammatory pathway in response to allergens 
entering the respiratory system.  The fact that asthma patients have decreased 
amounts of GSNO could result from overproduction of GSNOR causing an 
imbalance of NO and S-nitrosylated proteins; therefore activating the NF-κB 
pathway and consequently the immune response.  Inhibiting GSNOR would 
prevent the rapid removal of NO from S-nitrosylated proteins including IKKβ and 
therefore could impede the NF-κB pathway, slowing the immune response in 
asthma patients (Figure 5). 
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Figure 5.  NF-κB Pathway.  The NF-κB is a key transcription factor 
for the transcription of cytokines and chemokines. 
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IV. Small Molecule Inhibitors of GSNOR 
High-throughput screening was performed using ChemDiv Inc’s small 
molecule library of 60,000 compounds for inhibition of GSNOR activity in 
Chemical Genomics Core facility at Indiana University.  Recombinant GSNOR 
was expressed in E. coli and purified using a previously described method 
(Sanghani et al., 2000).  In high-throughput screening GSNOR activity was 
determined using 384 well plates with substrate octanol and cofactor NAD+.  The 
production rate of NADH absorbance at 340 nm was monitored.  Potential 
compounds were selected based on the ability to inhibit the activity of GSNOR 
and retested in the laboratory using an IC50 in vitro assay.  If the compound 
showed a 100 fold lower IC50 than the known inhibitor dodecanoic acid 
concentration in the IC50 in vitro test (Table 1) they were selected for further 
studies.  The small molecules were then tested for the inhibition of other ADHs, 
allowing selection of compounds that exclusively inhibit GSNOR (Table 2).  
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Compound 
Number %  inhibition 
IC50 at 
pH 7.5 
µM 
  pH 10 pH 7.5   
Dodecanoic acid 4 19 212 
C1 78 93 1.3 
C2 55 91 2.4 
C3 75 95 1.1 
 
Table 1.  In vitro Percent Inhibition and IC50 of C1, C2, C3.  The 
percent inhibition was determined using 2 conditions.  Inhibition 
studies at pH 10 were performed in 0.1 M sodium glycine (pH 10), 1 
mM octanol, 1 mM NAD+, 0.1 mM EDTA and 50 µM inhibitor.  
Inhibition studies at pH 7.5 were performed in 50 mM potassium 
phosphate pH 7.5 containing 15 µM NADH, 10 µM GSNO, 0.1 mM 
EDTA and 50 µM inhibitor. 
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Enzyme   % Inhibition 
  
C1 C2 C3 
GSNOR 
 
77 71 73 
ADH1B 
 
5 0 5 
ADH7 
 
4 13 8 
ADH4   6 1 3 
 
Table 2.  Compound Inhibition Comparison of ADHs.  Inhibition 
studies were performed in presence or absence of 5 µM inhibitor at 
25ºC in 50 mM potassium phosphate pH 7.5 containing 0.1 mM 
EDTA. The enzyme activity was measured by following the changes 
in absorbance at 340 nm. The values show the percent reduction in 
the enzyme activity caused by the inhibitor. The standard errors are 
below 15% of the averages shown, except when the inhibition was 
below 20%. Studies with ADH1B (β2β2-ADH), ADH7(σσ-ADH), 
ADH4 (π- ADH) were performed in 0.05 % DMSO. Studies with 
GSNOR were performed in presence of 1 % DMSO. 
 
 
From the in vitro IC50 and inhibition studies, three candidates, C1, C2, and 
C3, (Figure 6A-C) were selected and assessed ex vivo using RAW 264.7 
macrophage cells and A549 human carcinoma lung epithelial cells (Sanghani et 
al., 2009).  Of these three inhibitors all experiments were completed using C3.  
Inhibitor C2 experiments were performed during cytotoxicity, nitrosylation, and 
C1was only analyzed early in the studies, ie. cytotoxicity experiments.  Initially 
C3 showed higher level of protein nitrosolyation in cells making C3 our first 
choice.  Some experiments with C2 were included for comparison to C3.   
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Very little data for C1 was gathered because the results did not show sufficient 
nitrosylation in cell lysates compared to C2 and C3.  During ongoing experiments 
C3 seemed to exhibit more results, ie. detection of more nitrosolyation in cell 
lysates, more defined IκB experiments than C2 and C3.   
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C1 
 
C2 
 
C3 
 
Figure 6.  Inhibitors of GSNOR.  Structures of the GSNOR 
inhibitors C1; C2; C3. 
4-{[2-[(2-
cyanobenzyl)thio]-4-
oxothieno[3,2-
d]pyrimidin-3(4H)-
yl]methyl}benzoic acid 
 
3-[1-(4-acetylphenyl)-5-
phenyl-1H- pyrrol-2-
yl]propanoic acid 
5-chloro-3-{2-[(4-
ethoxyphenyl)(ethyl)amino] 
-2-oxoethyl}-1H-indole-2-
carboxylic acid 
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V. Biotechnology 
 Several biotechniques were utilized to obtain the data demonstrating the 
effects of inhibition of GSNOR on the NF-κB Pathway.  Western blot is a critical 
technique and can be used for protein identification and semi-quantitation.  
Therefore selection and dilution of antibody are essential for cell culture 
techniques such as sterility, plating and selection of cells, are also crucial.  ELISA 
and spectrophotometry were also utilized.   
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MATERIALS AND METHODS 
 
I. Cytotoxicity of GSNOR Inhibitors 
Cell Viability  
 Cell viability was determined using Promega CellTiter 96 AQueous One 
Solution Cell Proliferation Assay (Promega One Assay).  The Promega One Assay 
is a colormetric method determining viable cells by production of formazan which 
absorbs at 490 nm.  The production of formazan is directly proportional to the 
number of live cells.  Human lung adenocarcinoma epithelial cell line, A549 
(ATCC) was cultured in ATCC F-12K media containing 10% heat inactivated 
FBS and 1% pen/strep, at 37°C and in 5% CO2.  On day 1, 1500 A549 cells were 
plated in 100 μl medium per well of a 96-well tissue culture plate.  The next day 
cells were treated with 100 µl of inhibitor C3 diluted in medium, for a final 
concentration 0, 10, 30, 50, 80, 110, 150 µM and incubated for 4 hours at 37°C.  
TNFα was added to the cells to a final concentration of 10 ng/ml and incubated for 
5 days.  The medium was replaced with 120 μl of fresh media containing 20 μl of 
the Promega One Assay Reagent.  The cells were incubated again at 37 °C for 
1hour and then the absorbance was determined at 490 nm using a Molecular 
Devices SpectraMax 190 microplate reader.  
A second experiment was completed with minor changes to determine the 
cell viability for inhibitors C1, C2, C3.  The total time of treatment for this 
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experiment was 10 hours.  On day 1, 1500 A549 cells were plated in 100 μl 
medium per well of a 96-well tissue culture plate.  The next day cells were treated 
with 100 μl of inhibitor, C1, C2, or C3 diluted in medium, for a final concentration 
of 0, 10, 30, or 75 μM and incubated for 4 hours at 37°C.  TNFα was added to the 
cells to a final concentration of 10 ng/ml and incubated for an additional 6 hours at 
37°C.  Measurements were made using Promega One Assay reagent as described 
above. 
Cell Proliferation 
The cell proliferation was determined using Bromodeoxyuridine Cell 
Proliferation Assay kit (Calbiochem).  This assay uses Bromodeoxyuridine (BrdU) 
as a nucleoside to replace deoxythymidine in newly synthesized DNA produced in 
the S-phase of the cell cycle.  A549 cells were plated in 96-well plates at 1500 or 
4000 cells per well in 100 μl media and incubated overnight.  The cells were 
treated with 0, 0.3, 1, 3, 10, 30, 50, or 100 μM of C2 or C3 and incubated for 24 or 
48 hours at 37°C.  The relative amount of BrdU incorporated is then determined 
by an ELISA test using anti-BrdU monoclonal antibody and a secondary antibody 
conjugated with HRP.  The HRP product is proportional to the incorporated BrdU. 
 
II. Identification of S-nitrosylated Proteins  
On day 1, twelve 100 mm dishes were plated with 3 x 106 Raw 264.7 cells 
per dish in 10 ml of DMEM F-12 media (ATCC) + 10% heat inactivated fetal 
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bovine serum (Atlanta Biologicals) + 1% penicillin/streptomycin (Invitrogen).  On 
day 2, the medium in the dishes was replaced with 9 ml of fresh DMEM medium 
prior to treatment.  Cells were treated according to Table 3 to obtain a final 
concentration of, 33 µM for C3 and 1.1 µM for L-NAME.  Cells were incubated at 
37°C and 5% CO2 with these compounds for 2, 4, 8 or 24 hours then lysed with 
HEN lysis buffer (250 mM HEPES pH 7.7, 1 mM ethylenediaminetetraacetic acid 
(EDTA), 0.1 mM Neocupronine, 1% Nonidet P-40 (Sigma) and 10 mM S-methyl 
methanethiosulfonate (MMTS)).  Because of the photosensitivity of the SNOs’, all 
handling of samples after treatment was completed under special yellow lights. 
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Plate # Treatment Time 
1, 7 DMSO 4hr 
2, 8 C3 33 µM  2 hr 
3, 9 C3 33 µM  4hr 
4, 10 C3 33 µM + 1.1 µM L-NAME 
simultaneous treatment 
4hr 
5, 11 C3 33 µM  8 hr 
6, 12 C3 33 µM  24 hr 
 
Table 3.  Treatments of Raw 264.7 cells with C3. 
 
Lysate Preparation 
 After treatment, in controlled lighting, the medium was removed and the 
cells were washed twice with 10 ml of phosphate buffer saline (PBS). After 
removal of the PBS, cells were scraped off in 500 µl of freshly made HEN lysis 
buffer.  Lysate was placed in a microfuge tube and vortexed.  Samples were then 
centrifuged at 16,100 x g for 10 minutes at room temperature.  The supernatant 
(lysate) was removed, snap frozen using liquid nitrogen and stored at -20°C.   
Protein concentration of the lysates was determined by Bio-Rad Protein 
assay using 2.5 µl of lysate per assay and bovine serum albumin (BSA) as 
standard. 
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Biotin Switch Assay 
The lysates from the samples above were analyzed for S-nitrosothiols using 
the Biotin Switch Assay described by Jaffrey et al with a few modifications 
(Jaffrey and Snyder, 2001; Wang et al., 2008; Zhang et al., 2005).  The product of 
this assay switches the S-nitrosothiols with biotin.  To 200 µg of total protein from 
above lysates was added, 80 µl of 25% sodium dodecyl sulfate (SDS), 6 µl of 2 M 
MMTS (final concentration 10-15 mM MMTS) and Hen buffer to a total volume 
of 1 ml.  Samples were incubated in a 50°C water bath for 25 minutes with 
occasional vortexing.   
Five ml spin columns were prepared with Sephadex G25 resin equilibrated 
in chelexed PBS containing 1% SDS and 0.1 mM EDTA and centrifuged at 1000 
x g for 2 minutes to pre-pack the columns.  The samples were loaded onto the 
columns and centrifuged at 1000 x g for 2 minutes.  The eluant was sequentially 
passed through two additional spin columns.  The volume of the final eluant was 
measured and divided equally into 2 microfuge tubes, labeled A and B for the 
Biotin-HPDP labeling.  Two hundred µl of 4 mM biotin-HPDP + 250 µl of 
dilution buffer (100 mM HEPES pH 7.7, 2.5 mM EDTA, 0.25 mM Neocuproine) 
were added to tubes labeled A.  Two hundred µl of 4 mM Biotin-HPDP + 48 µl of 
500 mM ascorbic acid + 200 µl regular water + 25 µl saturated cuprous chloride 
(CuCl) were added to tubes labeled B for biotin labeling.  Both sets of tubes were 
kept in the dark at 25ºC for 3 hours.  Five ml spin columns containing Sephadex 
G25 resin, equilibrated with 25 mM HEPES pH 7.7, 100 mM NaCl, 1 mM EDTA 
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and 0.5% β-octyl glucoside (BOG) were pre-packed by centrifugation at 1000 x g 
for 2 minutes.  Samples were loaded onto the columns and centrifuged at 1000 x g 
for 2 minutes.  The eluant was then sequentially placed on two additional columns 
to remove free biotin.  Protein concentration was determined using 25 µl of each 
sample, using BCA Protein Assay (Pierce).  Five µg of each sample was 
transferred to a new tube and β-ME free Lamelli buffer was added in preparation 
for the SDS-PAGE/Western blot assay.   
Western Blot for Biotin Detection. 
 The biotin labeled lysate was analyzed by Western blot to establish the 
nitrosylation effect of the GSNOR inhibitors over selected time points.  Five µg of 
protein from samples described above was boiled for 5 minutes and centrifuged at 
16100 x g for 5 minutes.  One µg of protein was loaded on a precast 10% 
acrylamide Tris-HCl gel (BioRad).  Gel was electrophoresed for 2 hours at 120V.  
The proteins were immediately transferred to a PVDF membrane using the Bio-
Rad Criterion Transfer Blotting apparatus with Tris/Glycine buffer pH 8.3 
containing 10% methanol for 45 minutes at 100 V or overnight at 30V at 4°C.  
The blot was blocked with 5% milk in Tris buffered saline containing 0.1% Tween 
20 (TBS-T).  The blot was rinsed with TBS-T and probed with an anti-biotin HRP 
conjugated antibody (Sigma) for 1 hour at room temperature (RT).  The blot was 
rinsed 3 x 10 minutes with TBS-T and developed using ECL Plus 
chemiluminescence kit (GE Healthcare).   
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Streptavidin Precipitation 
 The remaining lysate of the samples which were used in the Biotin Switch 
assay was subjected to acetone precipitation.  The samples were centrifuged and 
the protein pellet was dissolved in 30 µl of 8 M guanidine and 170 µl of 10 mM 
potassium phosphate (KPi) pH 8.0.  Protein concentration was determined by the 
Bio-Rad Protein Assay using BSA as standard.   
 Twenty µl of streptavidin agarose resin (Pierce, Rockford, IL) equilibrated 
in 25 mM HEPES pH 7.7, 100 mM NaCl, 1 mM EDTA, and 1% BOG 
(neutralization buffer) were added to equal amounts of protein for all samples.  
The samples were diluted to 1 ml with neutralization buffer and incubated for 4 
hours at 4°C with shaking.  Samples/beads were centrifuged at 100 x g for 30 
seconds, supernatant discarded, the beads were then washed 5 x 1 ml of washing 
buffer (25 mM HEPES pH 7.7, 600 mM NaCl, 1 mM EDTA, 1% BOG).  The 
samples were incubated with Lamelli buffer containing 500 mM β-
mercaptoethanol (βME) for 2 hours at 40°C with shaking.  Samples were boiled 
for 5 minutes, centrifuged at 9300 x g for 5 minutes, and all of the supernatant was 
loaded on a Precast 10% acrylamide Tris-HCl gel (Bio-Rad). 
Western Blot of Streptavidin Precipitated Proteins 
 The SDS-PAGE gel was immediately transferred to a PVDF membrane 
using the Criterion Transfer Blotting apparatus (Bio-Rad) with Tris/Glycine buffer 
pH 8.3 with 10% methanol for 45 minutes at 100 V or overnight at 30 V.  The blot 
was blocked with 5% milk in Tris buffered saline and 0.1% Tween 20 (TBS-T).  
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The blot was rinsed with TBS-T and probed with the primary antibody IKKβ (Cell 
Signaling Technology) in 5% BSA-TBS-T overnight at 4°C.  The blot was rinsed 
3 x 10 minutes with TBS-T and incubated with HRP conjugated secondary 
antibody for 1 hour at room temperature, rinsed again 3 x 10 minutes with TBS-T.  
Blot bound HRP was detected using ECL Plus chemiluminescence kit (GE 
Healthcare).   
 
III. Effect of Inhibitor C3 on NF-κB Pathway Proteins 
Cell Treatment and Lysate Preparation 
Two hundred thousand A549 cells, (ATCC) were plated in 2 ml of F-12K 
Media containing 10% heat inactivated FBS and 1% pen/strep into 35 mm dishes.  
Next day, the medium was replaced with 2 ml of fresh medium prior to treatment.  
Samples were incubated with inhibitor C3 at concentrations of 0, 30, 50, or 100 
μM for 4 hours at 37°C then incubated with 10 ng/ml of the cytokine, TNFα, 
(Invitrogen) for 5 minutes at 37°C.  The medium was quickly removed and the 
cells were rinsed with cold PBS.  The cells were quenched with Lamelli buffer 
containing 50 mM NaF then extracted by scraping the dish clean.  Lysate was 
vortexed, centrifuged briefly, boiled for 5 minutes, centrifuged at 16,100 x g for 5 
minutes.  Equivalent volumes of sample supernatants were loaded onto a precast 
10% polyacrylamide Tris-HCl gel.  A second experiment was completed with pre-
treatment of C3 at concentrations 0, 50 and 100 µM for 4 hours.  At the 3 hour 
mark MG-132, a known proteasome inhibitor, was added to a final concentration 
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of 40 µM).  Then after 4 hours total, TNFα was added to specific samples for 5 
minutes at 10 ng/ml.  
Western Blot 
 The gel was transferred to a PVDF membrane and the membrane was 
blocked with 5% milk in TBS-T.  The blot was then probed overnight at 4°C with 
primary antibodies phospho-IκBα, IκBα, phospho-IKKα/β, and GAPDH (Cell 
Signaling Technology and Santa Cruz Biotechnology) in 5% BSA in TBS-T.  
Appropriate secondary antibodies conjugated with HRP were incubated for 1 hour 
at RT.  HRP was detected using ECL Plus chemiluminescence kit (GE 
Healthcare).   
 
IV. Proteins Affected by Inhibition of NF-κB Pathway 
Cell Extract Preparation 
A549 cells were plated at 50,000 cells per well of a 24 well plate in 1 ml of 
F12K Medium containing 10% heat inactivated FBS and 1% pen/strep on the day 
before treatment.  The cells were treated with 0, 10, 20, 30 and 50 μM of C3 for 4 
hours at 37°C.  TNFα was added to the appropriate wells for a final concentration 
of 10 ng/ml and incubated for 6 hours at 37°C.  The reaction was quenched using 
Lamelli buffer (no βME).  Cells were scraped from wells and placed in microfuge 
tubes.  Cell extracts were frozen overnight at -20°C.  Protein concentration was 
determined using BCA Protein Assay (Pierce).  Two μl of βME was added to each 
sample.  Samples were vortexed, boiled for 5 minutes centrifuged at 16,100 x g for 
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5 minutes.  Equivalent amounts of supernatant (30 μl) were loaded onto a precast 
10% acrylamide Tris-HCl gel. 
Western Blot 
 Gel was immediately transferred as written above.  The blot was probed 
with primary antibodies for ICAM, iNOS, COX2 and GAPDH (Santa Cruz 
Biotechnology) by incubating for 1-3 hours at RT.  The blot was rinsed with TBS-
T followed by incubation with the appropriate HRP conjugated antibody for 1 
hour at RT.  HRP signal on the blot was detected using ECL Plus 
chemiluminescence kit (GE Healthcare).   
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RESULTS 
 
I. Cytotoxicity of GSNOR Inhibitors  
Two methods were used to analyze the cytotoxicity of the inhibitors.  The 
first method Promega One Assay, determines the number of live cells by detecting 
the amount of NADPH or NADH produced and present in the cytosol of the cell.  
The NADH or NADPH of live cells is the electron donor which converts MTS 
tetrazolium to formazan.  The final product, formazan, is located in the cytoplasm, 
plasma membranes and other cellular compartments with a minor fraction in the 
mitochondria (Bernas and Dobrucki, 2002).  The second assay, BrdU Assay 
measures the cells that can replicate its DNA in the S-phase of the cell cycle.  The 
two types of assays were completed to determine the effect of the inhibitor on the 
cells.  Is the inhibitor detrimental to the cells in 10 hours, or over longer periods of 
time, 48 hours.  Both assays were used to determine how the inhibitor was 
affecting the cell ie. stopping replication or causing apoptosis.   
Cell Proliferation 
 Cell Proliferation was evaluated using the BrdU Assay to determine the 
cytotoxicity of the inhibitors.  The IC50 of C2 and C3 for the inhibition of A549 
cells was found to be 60 μM + 3 and 20 μM + 5 respectively (Figure 7 and 8).  
These data suggests that cell proliferation is interrupted during long continuous 
exposure to the inhibitor (48 hours).  This experiment also shows inhibitor C2 is 3 
fold less cytotoxic than C3. 
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Figure 7.  Inhibition of A549 cells by C2 using BrdU Incorporation.  
The IC50 of duplicate assays was analyzed using the BrdU Cell 
Proliferation Assay kit (Calbiochem).  The IC50 of the inhibitory 
compound C2 in A549 cells after incubating with the treatment for 
48 hours was 60 µM + 3 (n=12).  IC50 was calculated using equation 
Y=Bottom + (TOP-Bottom)/(1+(X/IC50)h) in GraphPad Prism 4. 
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Figure 8.  Inhibition of A549 cells by C3 using BrdU Incorporation.  
The IC50 of duplicate assays was analyzed using the BrdU Cell 
Proliferation Assay kit (Calbiochem).  The IC50 of the inhibitor C3 
was 20 μM + 5 (n=12), in A549 cells after 48 hours incubation with 
the compound. 
 
 Cell Viability 
The cell viability for inhibitor C3 was also determined using the Promega 
One Assay after 5 days of incubation with C3 in the presence or absence of TNFα.  
The IC50 of C3 without TNFα was 42 µM + 12 and 40 µM + 11 with TNFα 
(Figure 9).   
The BrdU Assay of inhibitor C3 gives an IC50 two times lower than the 
Promega One Assay (20µM vs 40 µM).  The difference of these results is 
attributed to the method of detection of cell cytotoxicity in the assays.  The BrdU 
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Assay measures the cell division by analyzing the new DNA synthesized while 
Promega One Assay analyzes the NADH production of the cell.  Live cells which 
are functional can produce NADH but may not be able to replicate.  
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Figure 9.  Inhibition of A549 cells by C3 with and without TNFα. 
The IC50 was analyzed using Promega CellTiter 96 AQueous One 
Solution Cell Proliferation.  The IC50 of the inhibitor C3 was 41 μM 
+ 11 (n=8), in A549 cells after 5 days of incubation the compound 
and in the prescence (42 µM +12) or absence (40 µM + 11) of 
TNFα. 
 
After determining the IC50 of the compounds, a cell viability experiment 
was designed to establish the condition of the A549 cells treated with inhibitors 
C1, C2, and C3, under experimental conditions.  The experimental conditions 
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were 4 hours of preincubation with cells and compound and then 6 additional 
hours with TNFα.  Most of the data collected to study the NF-κB pathway was 
conducted within these limits.  Inhibitors C1, C2, and C3 show a minimal change 
when normalized to untreated cells with a cell viability above 90% for the 
maximum inhibitor concentration tested, 75 µM (Figure 10).  This cell viability of 
90% provides confidence that the cells can withstand exposure to inhibitors C1, 
C2 and C3 when treated with TNFα for short time periods.  This information also 
provides confidence in the results of the data used to define the inhibitor C3’s 
effect on the NF-κB pathway.   
Figure 10.  Cell Viability after 10 hours of Incubation with Inhibitors.  
A549 cells were treated with C1, C2, or C3 at indicated 
concentrations for 10 hours (4 hours preincubation and additional 6 
hours after TNFα was added) and the viability was determined using 
the Promega CellTiter 96 AQueous One Solution Reagent. 
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II. Identification of S-nitrosylated Proteins  
 The effects of GSNOR inhibition on the S-nitrosylation of cellular proteins 
were examined using the Biotin Switch assay.  The nitrosylated proteins were 
labeled with biotin for analysis using the Biotin Switch Assay.  The Biotin Switch 
Assay is necessary because S-nitrosothiol groups are very unstable and easily lost 
during sample treatment.  This assay is a multiple step assay which removes the S-
nitrosothiol group linked to the cysteines and replaces it with biotin, see Figure 11.  
The detection of the biotin in the biotin + ascorbate samples in the following 
experiments would be equivalent to the analyzing S-nitrosothiol.  
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Figure 11.  Schematics of the Biotin Switch Assay.  Methyl 
methanethiosulfonate (MMTS) is first added to the lysate to block 
the free thiols (SH) of proteins with a methyl group.  After free 
MMTS is removed the sample is split and N-[6-
(Biotinamido)hexyl]-3´-(2´-pyridyldithio)propionamide (biotin-
HPDP) plus or minus ascorbate (ascorbate, a weak reduction agent, 
can specificly reduce S-nitrosothiols to thiols) is added to the 
sample.  These free thiols generated from SNO are then crosslinked 
with biotin using biotin-HPDP.  The free biotin-HPDP is removed 
by gel filtration.  
 
 
Raw 264.7 cells were treated with C2 or C3 for varied lengths of time, 
alone or in presence of nitric oxide synthase inhibitor, L-NAME (Sigma).  L-
NAME is an analog of arginine that inhibits the production of NO by inhibiting 
nitric oxide synthase.  The Western blots in Figure 12 shows that nitrosylated 
proteins accumulate with time in cells treated with compound C2 and C3.  The 
nitrosylation of intracellular proteins is evident following a 2 hour incubation with 
C3 and peaks at 8 hours before coming down to basal levels after 24 hours.  
Treatment with C2, nitrosylation peaked at 4 hours and back to basal levels at 12 
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hours.  The amount of SNOs is similar in untreated cells and those treated with 
both C2 and L-NAME or C3 and L-NAME simultaneously.  The L-NAME data 
illustrate the need of an active nitric oxide synthase to increase the accumulation 
of nitrosylated proteins and the inhibitor data suggest that inhibiting GSNOR 
increases the accumulation of large molecular weight SNOs in the cell.   
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A) 
 
B)  
 
Figure 12.  Nitrosylated Proteins after Treatment with C2 or C3.  
Cells were treated with 33 μM C2 or C3 for varied lengths of time 
(0, 2, 4, 8, 12 or 24 hours) alone or in combination with 1.1 mM L-
NAME for 4 hours (lane 4+N). At indicated times, the cells were 
quenched and the lysate was analyzed for S-nitrosothiol content by 
the biotin switch assay.  Equal amounts of proteins were loaded in 
each lane and the degree of biotinylation (and hence S-nitrosylation) 
determined using an anti-biotin antibody.  A) A549 cells treated with 
C2;  B) RAW 264.7 cells treated with C3. 
 
Time hrs 
Ascorbate 
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With the results of S-nitrosolyated proteins increasing with time in cells 
treated with C2 or C3, the next step was to examine the effects of GSNOR 
inhibition on proteins reported to be affected by nitrosylating agents like S-
nitrosoglutathione or S-nitrosocysteine.  Several proteins in the NF-κB signaling 
pathway have been reported to be regulated by S-nitrosylation (Reynaert et al., 
2004).  Inhibitor Kappa B Kinase beta (IKKβ) was reported to be the most 
upstream nitrosylated protein in the NF-κB activation pathway.  The effect of 
GSNOR inhibition on the S-nitrosylation of IKKβ was studied in RAW 264.7 cells 
using the biotin switch assay.  
 The biotinylated proteins were isolated using streptavidin agarose and 
subjected to Western blotting for the detection of specific proteins.  The Western 
blot in Figure 13 shows IKKβ to be nitrosylated in RAW 264.7 cells following the 
inhibition of GSNOR with C3. The extent of S-nitrosylation of IKKβ also 
increased with the length of exposure of cells to C3.  Concomitant treatment of 
cells with L-NAME and C3 did not change the S-nitrosylation level of IKKβ.  
This suggests the inhibition of GSNOR with C3 increases the accumulation of 
nitrosylated IKKβ over time but does not nitrosylate IKKβ. 
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Figure 13.  S-nitrosylated IKKβ of Treated Samples Following 
Treatment with C3.  RAW 264.7 cells were treated with C3 for 0, 2, 
4, 8 hours and 4 hours + L-NAME.  After the S-nitrosylated proteins 
were labeled with Biotin, equal amounts of protein were precipitated 
using streptavidin agarose beads.  The above Western blot was 
probed with anti-IKKβ antibody to demonstrate the effect of the 
inhibitor on the nitrosylation of protein IKKβ. 
 
III. Effect of Inhibitor C3 on IKKβ Activity 
 The inhibition of GSNOR does affect the nitrosylation of IKKβ in A549 
cells, but will this nitrosylation affect the activity of IKKβ?  To determine if and 
how nitrosylation of IKKβ would affect its activity and signaling in the NF-κB 
pathway, cells were treated with C3 and then TNFα.  TNFα stimulates the TNF 
receptor in the plasma membrane which initiates a cascade of kinase activity in the 
cytoplasm that phosphorylates IKKβ which phopsphorylates the Inhibitor kappa B 
protein (IκB).  This phosphorylation of IκB, (pIκB) activates the ubiquination and 
proteasome degradation of IκB releasing and therefore allowing the translocation 
of NF-κB to the nucleus, Figure 5.  If the activity of IKKβ is affected, a difference 
in the extent of phosphorylation of IκB should be detectable.  The Western blot in 
Figure 14 demonstrates the effect of C3 on the phosphorylation of IκB in A549 
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cells.  The amount of phosphorylation of IκB from TNFα stimulated cells appears 
to be the same as the untreated cells (Figure 14A).  But after probing for IκB 
which identifies both IκB and pIκB, the blot shows a significant increase in total 
IκB with increasing concentrations of GSNOR inhibitor (n=6 * p < 0.05, ** p< 
0.01) (Figure 14B).  The higher amount of total IκB could be due to decreased 
IKKβ activity or decreased proteasomal degradation of IκBα preventing the 
release of NF-κB. 
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A)  
 
 
 
 
               
  
 
 
 
 
  
Figure 14.  Effect of C3 on the Phosphorylation of IκB.  A) 
Western Blot of A549 cells treated with C3 (0, 30, 50, 100 μM) for 
4 hours, then 10 ng/ml of TNFα for 5 minutes or just compound 
alone or control.  B) Analysis of Western Blot using a densitometer 
(Quantity One Bio-Rad System) and a magnification of the TNFα 
treated samples, *p< 0.05, **p<0.01 using GraphPad Prism 4 one 
way anova and Tukey t-test statistics on 6 sets of data from 3 
independent experiments.  
B) 
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The addition of proteasome inhibitor, MG-132, in the last hour of the C3 
pretreatment (Figure 15) illustrates a much better account of the reaction of the 
cells to compound C3.  The accumulation of pIκB in cells treated with TNFα and 
MG-132 demonstrates inhibition of proteasomal degradation of IκB.  When cells 
are treated with compound C3, MG-132, and TNFα, the amount of pIκB decreases 
significantly with increasing concentrations of compound C3 and total IκB appears 
unchanged.  In conclusion, the decreased phosphorylation of IκBα in the presence 
of compound is most likely due to decreased IKKβ activity and not due to 
decreased proteasomal activity. 
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Figure 15.  Effect of C3 on the Phosphorylation of IκB in the 
Presence of a Proteasome Inhibitor.  A549 cells were treated with C3 
as in Figure 14A plus a known proteasome inhibitor MG-132 1 hour 
prior to TNFα treatment.  Graph average of 2 sets of data. 
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A dose-dependent increase in nitrosylation of IKKβ was shown in Figure 
13.  Next, we investigated whether increased nitrosylation affects phosphorylation 
of IKKβ or total amount of IKKβ.  As shown in Figure 16 no change in 
phosphorylation of IKKβ and no major difference in the accumulation of IKKβ 
with increasing amounts of C3 was observed.  This would suggest that 
nitrosylation of IKKβ affects its activity but not due to a decrease in 
phosphorylation. 
                        
 
 
 
Figure 16.  IKKβ Phosphorylation in A549cells.  A549 cells treated 
with 0, 30, 50, 100 μM of C3 for 4 hours and 10 ng/ml of TNFα for 
5 minutes assayed by Western blot and probed with anti-pIKKβ, 
anti-IKKβ and anti-GAPDH antibodies.    
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IV. Proteins Affected by Inhibited NF-κB Pathway 
 ICAM is one of the proteins whose expression is regulated by the 
transcription factor NF-κB.  To observe the effects of this protein after inhibiting 
GSNOR, A549 cells were incubated with inhibitor C3 at varying concentrations 
and the NF-κB pathway was induced by TNFα.  The amount of ICAM-1 produced 
decreased, with increasing concentrations of inhibitor C3 (Figure 17).  This data 
reveals that C3 inhibits the NF-κB pathway. 
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Figure 17.  Expression of ICAM-1 is Regulated by NF-κB.  
Increasing the concentration of inhibitor C3, decreases the amount 
of ICAM-1 in the A549 cells pre-treated for 6 hours with C3and 
then an additional 4 hours with TNFα.  Statistics on 3 sets of data, 
*p<0.05 and **p<0.01. 
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DISCUSSION 
 
I. Inhibitors of GSNOR 
The cytotoxicity of GSNOR inhibition is not known.  After 48 hours of 
exposure, GSNOR inhibitors C2 and C3 demonstrate a moderate cytotoxicity level 
on the lung epithelial carcinoma cells at low concentrations by hindering cell 
proliferation.  Compounds inhibiting GSNOR activity could be a potential 
cytotoxic drug at higher concentrations.  Cell viability under experimental 
conditions revealed live cells for the duration of the experiments.  These specific 
inhibitors, C2 and C3 present the possibility of being used for other purposes, 
since the nitrosylation effects returned to normal levels within 24 hours (Figure 
12).  Recovery from drug treatment is important to cell viability and will allow 
flexibility in the formulation of a final marketable drug treatment.   
Protein nitrosylation is a post translational modification.  Nitric oxide 
synthases (NOS) generate nitric oxide, which in turn nitrosylates proteins, peptides 
and amino acids.  The S-nitrosylated proteins are called protein-SNO.  These 
protein-SNO and the direct effects of NO regulate several biological functions 
such as smooth muscle tone, inflammation, apoptosis and others (Figure 18).  The 
nitroso group from the proteins is transferred to glutathione (GSH) forming S-
nitrosoglutathione (GSNO).  GSNO can then be converted to GSSG and NH2OH  
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in the presence of NADH and deplete the GSNO pool.  By degradation of GSNO, 
GSNOR plays an important role in balancing the amount of GSNO and ultimately 
protein-SNO.  
 
 
 
Figure 18.  NO Bioactivity and Signaling Pathway.  Role of GSNOR 
inhibition on the NO Signaling Pathway and possibly the bioactivity of NO. 
 
The inhibition of GSNOR will therefore increase the cellular concentration 
of GSNO and therefore indirectly increases the amount of nitrosylated proteins.   
Several GSNOR inhibitors were identified in our laboratory and the aim of 
this study was to understand their cellular effects.  One of the experiments studied 
the effect of the compound on protein-SNO.  As shown in Figure 12, we observed 
a time dependent increase in protein-SNO.  In the same experiment, the treatment 
with GSNOR inhibitor plus L-NAME inhibited accumulation of nitrosylated 
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proteins in comparison with the same condition without L-NAME.  Since L-
NAME is known to inhibit nitric oxide synthases (NOS), this result substantiates 
that NOS activity is necessary for the observed increase in cellular nitrosylation.  
This would also indicate that inhibiting GSNOR does not directly increase 
nitrosylation of proteins but prevents the transfer of NO by decreasing the levels 
of GSNO.   
Next we focused on identification of nitrosylated proteins using protein 
specific antibodies.  As shown in Figure 13 we identified nitrosylation of IKKβ 
(Figure 19 Step A).  So the question raised was whether nitrosylation of IKKβ 
affects its activity.  IKKβ is responsible for phosphorylation of IκBα and 
phosphorylation of IκBα results in its degradation and activation of NF-κB 
pathway.  Therefore, we studied the phosphorylation of IκBα in the presence of 
inhibitor C3.  After treatment with C3, we expected pIκB levels to be decreased 
due to nitrosylation of IKKβ.  Instead we discovered pIκB amounts were 
equivalent in C3 treated and untreated cells.  However, we did see an increase in 
total IκBα (Figure 14).  To confirm that the accumulation of IκB was due to 
decreased phosphorylation and not due to inhibition of proteasomal degradation, 
cells were treated with inhibitor C3 and MG-132, a known proteasome inhibitor.  
If the decreased degradation of IκBα was due to inhibition of proteasome then the 
concentration of C3 should not affect the pIκBα in the presence of MG-132.  As 
shown in Figure 15 we observed a dose-dependent decrease in pIκB.  Because of 
this dose-dependent decrease of pIκB, the direct inhibition of proteasomal 
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degradation by the compounds is eliminated (Figure 19 Step B).  Therefore, 
inhibition of IKKβ activity is most likely responsible for the decreased 
phosphorylation of IκBα (Figure 19 Step C).  So the next question was whether the 
phosphorylation of IKKβ was affected by nitrosylation (Figure 19 Step D).  As 
seen in Figure 16 we did not detect any change in pIKKβ with different 
concentrations of C3 (Figure 1).     
 
 
 
Figure 19.  NF-κB Pathway.  Effects of inhibiting GSNOR on the 
NF-κB pathway.  
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In agreement with our results, inhibition of IKKβ through S-nitrosylation 
has been documented (Reynaert et al., 2004).  The activity of IKKβ is inhibited by 
S-nitrosylation, of the Cys-179 which is between the two phosphorylated serine 
residues, Ser-177 and Ser-181 (Reynaert et al., 2004).  The S-nitrosylation of this 
cysteine could be hindering the active site of the IKKβ or affectin its structural 
conformation.   
Another potential question would be if IKKβ activity is inhibited by direct 
binding of compound to IKKβ.  In a separate experiment done in our lab (data not 
shown) we showed by an in vitro assay that IKKβ activity could not be inhibited 
by the compounds.   
  To determine if the decreased degradation of IκBα caused by C3 translated 
into decreased NF-κB activity we studied the expression of ICAM, one of the 
proteins whose expression is regulated by the transcription factor NF-κB.  We 
found a dose-dependent decrease in amounts of ICAM-1 with increasing C3 
concentration after 10 hours of exposure (Figure 17).  In a separate experiment we 
also studied the effect of C3 on a stable transfected cell line containing a luciferase 
gene under control of NF-κB, once again we found a dose-dependent decrease in 
luciferase activity with increasing concentration of C3 (data not shown). 
Together this data supports the premise that the activity of transcription factor NF-
κB is suppressed by inhibiting GSNOR with compound C3 (Figure 19 Step E). 
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II. Biotechnology  
 During the experimental procedures, several biotechniques were utilized, 
Western blots, cell culture, ELISA, and gel filtration.  Western blots were a major 
module for detecting changes in protein expression as a result of treatment with 
GSNOR inhibitors.  Choice of antibodies is critical in Western blots.  Antibodies 
can vary from company to company, and lot to lot.  We found that NF-κB pathway 
proteins antibodies from Cell Signaling Technology were more reliable than other 
sources.  Western blots can be very selective, ie. monoclonal antibodies, for the 
detection of proteins as well as extremely sensitive to the amount of the protein.  
Monoclonal antibodies are specific for the chosen protein using a unique peptide 
segment.  The monoclonal antibody will only bind to a selected peptide and 
therefore only one antibody binds to one molecule of protein.  This will weaken 
the signal of the antibody and possibly miss a low abundance protein.  Polyclonal 
antibodies can bind to several different peptides on a protein and therefore provide 
a larger signal.  Polyclonal antibodies might bind other nonspecific proteins.  The 
dilution of the antibody was also critical.  If the antibody concentration was too 
low, the signal would be very low and difficult to obtain.  If the concentration of 
the antibody was too high, the blots would show a lot of nonspecific signals which 
could interfere with the specific protein you were trying to detect.  The protein 
transfer electrophoresis was also very critical in Western blots.  The allotted time 
for transferring was important.  If the transfer was not complete, proteins were left 
behind in the gel.  If the transfer was too long the protein will go through the 
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membrane and onto the filters.  Western blots have more specificity in selecting 
multiple targets than an ELISA or a UV/Vis spectrophotometry protein assay. 
 Cytotoxicity testing with both Promega One Assay and the BrdU Assay 
was important.  Both assays are based on different principles. 
 The data analysis for quantitation using ELISAs are less variable.  The 
issue with ELISAs were that they are time consuming and require developing the 
conditions for the experiment, selection of antibody, its concentration, standard 
curve, etc. 
 Protein Assays can be critical to the analysis of data.  Several techniques, 
such as Western blots, are dependent on the amount of protein loaded onto the gel.  
Some buffers and detergents used to prepare samples can interfere with the protein 
assay, ie.  Bradford protein assay is much more sensitive to the amount of Sodium 
dodecyl sulfate (SDS) in the sample being analyzed compared to BCA assay 
where SDS does not interfere with the results. 
 Cell culture techniques played a major role in obtaining data for 
examining various hypotheses.  Sterility in cell culture is critical since 
contamination such as bacteria, mycoplasma and other cell lines, invalidate the 
results.  Cell culture is used as a middle step between in vitro and whole animal 
studies.  Cell culture will demonstrate the potential results under endogenous 
conditions compared to in vitro results.  Cell culture is used for testing several 
different conditions quickly.  Cell culture is much cheaper and humane than whole 
animal studies.  Counting and plating cells is critical for consistency within an 
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experiment as well as reproducibility between experiments.  In cell culture, 
specific functioning cells can be tested ie. hepatocytes of the liver to epithelial 
cells from the lungs.  In our studies two cells lines were chosen, mouse Abelson 
murine leukemia virus transformed macrophage cells, RAW 264.7 and human 
lung carcinoma epithelial cell line, A549.  The RAW 264.7 cells are known as the 
cytokine-treated murine macrophage which has been established as a prototype for 
studying NO-related metabolic pathways for nitrosative stress in mammalian cells 
(Eu et al., 2000).  
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CONCLUSION 
 
 Activation of NF-κB pathway by TNFα is a well defined:  IKKβ activation 
by phosphorylation which then phosphorylates IκB, ubiquination and 
consequently degradation of pIκB from the cytosolic IκB-NF-κB complex by 
Proteasome 26.  This degradation of IκB exposes the nuclear translocation domain 
allowing NF-κB to enter the nucleus.  Once in the nucleus, NF-κB is the 
transcription factor and main regulator of the immune response proteins, cytokines 
and chemokines (Janssen-Heininger et al., 2009).    
 The research provided above supports the suggested hypothesis that 
inhibiting GSNOR by C3 will suppress the activation of the transcription factor 
NF-κB indirectly through the regulation of S-nitrosylation of IKKβ.  
Future Therapy for Asthma Patients 
 GSNOR activity is specifically inhibited by C2 and C3.  Given that 
GSNOR has been declared an “important regulator of Human Asthma” (Que et al., 
2009) managing the activity of this enzyme through inhibition could be a major 
advancement in Human Asthma relief and other lung diseases (Staab et al., 2009) 
Perhaps with key formulation design of the inhibitor, GSNOR can be regulated 
using C2 or C3 as a future treatment for asthma.  
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